Paper41681925
The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System.
Wendler J and 11 others. Cancers (Basel), 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System. Papers, record 41681925. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41681925
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| n.a. | AbbVie (Germany) | PubMed | ||
| n.a. | Roche Pharma AG (Germany) | PubMed |
Source PubMed
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37215448 | Venetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia Patients. | J Cancer | 2023 | https://conductscience.org/library/papers/37215448 | PubMed |
| 2 | 26239089 | Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. | Blood | 2015 | https://conductscience.org/library/papers/26239089 | PubMed |
| 3 | 35562406 | Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. | Leukemia | 2022 | https://conductscience.org/library/papers/35562406 | PubMed |
| 4 | 38836097 | Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Hemasphere | 2024 | https://conductscience.org/library/papers/38836097 | PubMed |
| 5 | 27132696 | Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. | Lancet Haematol | 2016 | https://conductscience.org/library/papers/27132696 | PubMed |
| 6 | 27407096 | Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/27407096 | PubMed |
| 7 | 28325865 | Venetoclax and obinutuzumab in chronic lymphocytic leukemia. | Blood | 2017 | https://conductscience.org/library/papers/28325865 | PubMed |
| 8 | 24346116 | Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. | Cancer Discov | 2014 | https://conductscience.org/library/papers/24346116 | PubMed |
| 9 | 25916698 | Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas. | Leuk Res | 2015 | https://conductscience.org/library/papers/25916698 | PubMed |
| 10 | 35004280 | Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series. | Front Oncol | 2021 | https://conductscience.org/library/papers/35004280 | PubMed |
| 11 | 35732829 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. | Leukemia | 2022 | https://conductscience.org/library/papers/35732829 | PubMed |
| 12 | 37322012 | Primary central nervous system lymphoma. | Nat Rev Dis Primers | 2023 | https://conductscience.org/library/papers/37322012 | PubMed |
| 13 | 33560416 | Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). | Neuro Oncol | 2021 | https://conductscience.org/library/papers/33560416 | PubMed |
| 14 | 12393404 | Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. | Blood | 2003 | https://conductscience.org/library/papers/12393404 | PubMed |
| 15 | 38301670 | High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial. | Lancet Haematol | 2024 | https://conductscience.org/library/papers/38301670 | PubMed |
| 16 | 34699590 | Primary central nervous system lymphoma. | Blood | 2022 | https://conductscience.org/library/papers/34699590 | PubMed |
| 17 | 32583848 | Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. | Neuro Oncol | 2021 | https://conductscience.org/library/papers/32583848 | PubMed |
| 18 | 39286959 | Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients. | Clin Transl Sci | 2024 | https://conductscience.org/library/papers/39286959 | PubMed |
| 19 | 30698644 | Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. | Ann Oncol | 2019 | https://conductscience.org/library/papers/30698644 | PubMed |
| 20 | 29986852 | Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. | Blood Adv | 2018 | https://conductscience.org/library/papers/29986852 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| KRT20 | 54474 | PubTator's text mining | https://conductscience.org/library/genes/54474 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41681925
GET https://conductscience.org/api/papers/v1/41681925/references?page=2